<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>08032472012597</udiDi>
    <basicUdiDi>8032472BIOANAby2AA</basicUdiDi>
    <tradeName>Neobianacid</tradeName>
    <deviceName>Neobianacid</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472012597</reference>
    <placedOnMarketCountry>Slovenia</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:29.227Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472012313</udiDi>
    <basicUdiDi>8032472LENOby232</basicUdiDi>
    <tradeName>Lenodiar Kinder</tradeName>
    <deviceName>Antidiarroico pediatric</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472012313</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:23.225Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472011903</udiDi>
    <basicUdiDi>8032472LENOby232</basicUdiDi>
    <tradeName>Lenodiar Pediatric</tradeName>
    <deviceName>Antidiarroico pediatric</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472011903</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:22.059Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472007944</udiDi>
    <basicUdiDi>8032472BIOANAby2AA</basicUdiDi>
    <tradeName>Neobianacid</tradeName>
    <deviceName>Neobianacid</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472007944</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:20.822Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472006916</udiDi>
    <basicUdiDi>8032472BIOANAby2AA</basicUdiDi>
    <tradeName>Neobianacid</tradeName>
    <deviceName>Neobianacid</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472006916</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:19.625Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472006893</udiDi>
    <basicUdiDi>8032472BIOANAby2AA</basicUdiDi>
    <tradeName>Neobianacid</tradeName>
    <deviceName>Neobianacid</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472006893</reference>
    <placedOnMarketCountry>Belgium</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:13.628Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472006879</udiDi>
    <basicUdiDi>8032472BIOANAby2AA</basicUdiDi>
    <tradeName>Neobianacid</tradeName>
    <deviceName>Neobianacid</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472006879</reference>
    <placedOnMarketCountry>Greece</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:12.418Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472006855</udiDi>
    <basicUdiDi>8032472BIOANAby2AA</basicUdiDi>
    <tradeName>Neobianacid</tradeName>
    <deviceName>Neobianacid</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472006855</reference>
    <placedOnMarketCountry>Romania</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:11.252Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472006831</udiDi>
    <basicUdiDi>8032472BIOANAby2AA</basicUdiDi>
    <tradeName>Neobianacid</tradeName>
    <deviceName>Neobianacid</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472006831</reference>
    <placedOnMarketCountry>Portugal</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:10.021Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472006817</udiDi>
    <basicUdiDi>8032472BIOANAby2AA</basicUdiDi>
    <tradeName>Neobianacid</tradeName>
    <deviceName>Neobianacid</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472006817</reference>
    <placedOnMarketCountry>Poland</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:04.006Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472006794</udiDi>
    <basicUdiDi>8032472BIOANAby2AA</basicUdiDi>
    <tradeName>Neobianacid</tradeName>
    <deviceName>Neobianacid</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472006794</reference>
    <placedOnMarketCountry>Bulgaria</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:02.815Z</lastUpdated>
  </row>
  <row>
    <udiDi>08032472006664</udiDi>
    <basicUdiDi>8032472BIOANAby2AA</basicUdiDi>
    <tradeName>Neobianacid</tradeName>
    <deviceName>Neobianacid</deviceName>
    <manufacturerName>ABOCA S.P.A. SOCIETÀ AGRICOLA</manufacturerName>
    <manufacturerSrn>IT-MF-000029499</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>08032472006664</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:25:01.926Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649993626250</udiDi>
    <basicUdiDi>7649993626FT42306VN</basicUdiDi>
    <tradeName>Lefaxan Protect</tradeName>
    <deviceName>Sectacol</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>F12B02E015</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:13:39.661Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649993626236</udiDi>
    <basicUdiDi>7649993626FT42306VN</basicUdiDi>
    <tradeName>Lefaxan Protect</tradeName>
    <deviceName>Sectacol</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C12B02E030</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:13:33.648Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649993626229</udiDi>
    <basicUdiDi>7649993626FT42306VN</basicUdiDi>
    <tradeName>Lefaxan Protect</tradeName>
    <deviceName>Sectacol</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C12B02E015</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:13:32.456Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649993626137</udiDi>
    <basicUdiDi>7649993626FT42306VN</basicUdiDi>
    <tradeName>SECTACOL</tradeName>
    <deviceName>Sectacol</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C12B02E003</reference>
    <placedOnMarketCountry>Hungary</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:13:31.250Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649993626113</udiDi>
    <basicUdiDi>7649993626FT42307VQ</basicUdiDi>
    <tradeName>Gelselax</tradeName>
    <deviceName>Gelselax</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C20B02E030</reference>
    <placedOnMarketCountry>Finland</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:13:30.045Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649993626106</udiDi>
    <basicUdiDi>7649993626FT42307VQ</basicUdiDi>
    <tradeName>Gelselax</tradeName>
    <deviceName>Gelselax</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C20B02E015</reference>
    <placedOnMarketCountry>Hungary</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:13:24.045Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649993626090</udiDi>
    <basicUdiDi>7649993626FT42307VQ</basicUdiDi>
    <tradeName>Gelselax</tradeName>
    <deviceName>Gelselax</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C20B02E008</reference>
    <placedOnMarketCountry>Hungary</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:13:22.849Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649993626076</udiDi>
    <basicUdiDi>7649993626FT42306VN</basicUdiDi>
    <tradeName>SECTACOL</tradeName>
    <deviceName>Sectacol</deviceName>
    <manufacturerName>DEVINTEC SAGL</manufacturerName>
    <manufacturerSrn>CH-MF-000020271</manufacturerSrn>
    <authorisedRepresentativeName>DEVINTEC HEALTH S.L.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>ES-AR-000020256</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C12B02E030HU</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:13:21.653Z</lastUpdated>
  </row>
</eudamedExport>